CD47 and myelodysplastic syndrome: AUR103 calcium (ClinicalTrials.gov identifier: NCT05607199), TQB2928 (ClinicalTrials.gov identifier: NCT06008405), and AK117 (ClinicalTrials.gov identifier: NCT06387420) are other CD47 antagonists that are currently under evaluation in phase-1 and phase-1b/2 clinical trials, in association with azacitidine or azacitidine and venetoclax in patients with AML and MDS [148,149,150].